Highest-materiality recent filing
Elite Pharmaceuticals launches generic Requip XL; addresses $10M U.S. market
Launched generic Ropinirole Extended-Release Tablets (2, 4, 6, 8, 12 mg) for Parkinson's disease.
Elite Pharma reports FY2026 revenue of $148.9M (+77% YoY), operating income $49.1M (+151%)
Consolidated revenue $148.9M, up $64.8M (77%) vs prior year; operating profit $49.1M, up $29.5M (151%).
Elite Pharmaceuticals reports positive bioequivalence for undisclosed anticonvulsant generic drug
Pivotal BE study successful; generic product bioequivalent to branded anticonvulsant under fasting conditions.
Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available
ANDA submitted to FDA for generic version of an undisclosed anticoagulant drug product.
Elite Pharma Q3 FY2026 revenue up 120% to $31.6M; net income $18.6M
Revenue $31.6M, +120% YoY; income from operations $9.0M, +721% YoY.
Elite Pharma Q2 FY2026 revenue $36.3M (+92% YoY); operating income $8.2M (+136% YoY)
Consolidated revenue $36.3M for quarter ended Sept 30, 2025, up $17.4M or 92% vs prior year.
Elite Pharmaceuticals receives FDA approval for generic Requip XL (ropinirole ER) tablets
FDA approved ANDA for generic Requip XL (Ropinirole Extended-Release Tablets USP) in 2,4,6,8,12 mg strengths.
Elite Q1 revenue $40.2M, up 114% YoY; operating profit $21.7M, up 462%
Consolidated revenues of $40.2M for Q1 FY2026, a 114% increase YoY from the prior year comparable period.
Elite Pharma FY2025 revenue $84.0M (+48% YoY); operating profit $19.6M (+81% YoY)
Consolidated revenue for FY2025 (ended March 31, 2025) was $84.0M, up 48% from $56.6M prior year.
Positive pivotal bioequivalence results for an undisclosed generic anticoagulant; product is bioequivalent to brand.
Elite launches generic Percocet (oxycodone/acetaminophen) tablets in 3 strengths
Launched generic oxycodone HCl/acetaminophen tablets in 5/325, 7.5/325, and 10/325 mg strengths.
Elite Pharmaceuticals ships first product from new FDA-approved expanded campus
First lot of finished product shipped from new facility at 144 Ludlow Avenue, Northvale, NJ.
Elite Pharma Q3 fiscal 2025 revenue $14.4M (-8% YoY); operating profit $1.1M (-69%)
Consolidated revenue $14.4M for quarter ended Dec 31, 2024, down 8% from $15.6M in prior-year period.
Elite Launches Generic Vyvanse (Lisdexamfetamine) in 7 Strengths for ADHD
Elite launched generic lisdexamfetamine (Vyvanse) in 10, 20, 30, 40, 50, 60, 70 mg capsules.
Elite Pharmaceuticals launches generic Norco (hydrocodone/acetaminophen) tablets
Launched generic Norco (hydrocodone bitartrate/acetaminophen) in 2.5/325, 5/325, 7.5/325, and 10/325 mg strengths.
Elite Pharma gets FDA nod for generic Vyvanse; $4.3B market
Received FDA approval on November 15, 2024 for ANDA for generic Lisdexamfetamine Dimesylate (Vyvanse) in 7 strengths (10-70 mg capsules).
Elite Pharma Q2 FY2025 revenue $18.9M (+33% YoY); operating profit $3.5M (+84%)
Consolidated revenue $18.9M for Q2 ended Sep 30, 2024, up $4.7M or 33% vs prior year.
Israeli Ministry of Health approves Elite's generic Adderall; first shipment months away
Israeli Ministry of Health approved Elite's generic Adderall (mixed amphetamine salts) in 10mg, 20mg, 30mg tablets on Oct 7, 2024.
Elite Pharma Q1 FY2025 revenue up 109% YoY to $18.8M; operating profit +144%
Revenue of $18.8M for Q1 ended June 30, 2024, compared to $9.0M in Q1 FY2024.
Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)
Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.
Elite Pharma receives FDA approval for generic Methotrexate; market $64.3M annual sales
FDA approved ANDA for generic Methotrexate Sodium 2.5 mg tablets on May 16, 2024.
Elite Pharma Q3 revenue up 68% to $15.5M; operating profit up 80% to $3.5M
Revenue $15.5M for Q3 FY2024 ended Dec 31, 2023, +68% YoY from $9.2M.
Elite Pharma Q2 FY2024 revenue $14.2M (+64.9% YoY); net income $14.9M (+886%)
Consolidated revenue of $14.2M for Q2 ended Sep 30, 2023, up 64.9% YoY.
Elite Pharmaceuticals files ANDA for generic opiate analgesic with $720M market
Filed ANDA with FDA on August 17, 2023 for a generic opiate analgesic product.
Elite Pharmaceuticals reappoints Carter Ward as CFO effective Sept 5, 2023
Carter Ward reappointed CFO, secretary, treasurer; previously served from July 2009 to May 2021.
Elite Pharma Q1 revenue up 17% to $9.0M; net income up 267% to $1.1M
Revenue $9.0M (+16.9% YoY); operating profit $1.6M (+60% YoY).
Elite Pharmaceuticals CFO Robert Chen resigns; search underway for replacement
CFO Robert Chen notified intent to resign on February 25, 2023.
Elite Pharmaceuticals sells rights to generic Sabril (vigabatrin) ANDA to Pyros
Sale of rights to approved ANDA for generic Sabril (Vigabatrin Powder for Oral Solution, 500 mg) to Pyros Pharmaceuticals.
On September 5, 2023 (the “Effective Date”), Carter J. Ward was appointed as the Company’s chief financial officer, secretary, and treasurer.
On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.
On April 27, 2023, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Mark Pellegrino to serve as the Registrants’ Chief Financial Officer effective May 1, 2023, replacing Robert Chen.
On February 25, 2023, Robert Chen notified Elite Pharmaceuticals, Inc. (the “Company”) of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary.
On September 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Kirko Kirkov to serve as the Registrants’ Chief Commercial Officer effective September 6, 2022.
On May 5, 2022, Elite Pharmaceuticals, Inc., a Nevada corporation (the “Registrant”), entered into an employment agreement with Robert Chen to serve as the Registrants’ Chief Financial Officer, replacing Marc Bregman, who served as the Registrant’s Chief Financial Officer effective May 16, 2022.
Effective as of May 16, 2022, Mr. Chen replaced Mr. Bregman as the Registrant’s Chief Financial Officer, and Mr. Bregman, who also served as the Registrant’s Secretary and Treasurer, ceased providing services to the Registrant in such capacities as of April 29, 2022.
On April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc. (the “Company”) of his intent to leave the Company and resign from his position as Chief Financial Officer, Treasurer and Secretary to pursue another opportunity.
Max materiality 0.80 · Median 0.60 · Most common event other_material